Lupin developing new products to treat cancer, other disease

Drug maker Lupin is in the process of developing a pipeline of products under its new drug discovery programme to treat various diseases like cancer and metabolic disorders, a top company official said.
 The company, which last month inked a partnership with global pharma company AbbVie for the development and commercialisation of its novel oncology drug to treat hematological cancers, is focussing on first-to-market kind of opportunities with its new products.
 "The Novel Drug Discovery and Development (NDDD) is focused and committed on developing a pipeline of highly differentiated and innovative new chemical entities in various therapeutic areas like oncology, immunology and metabolic disorders," Lupin President NDDD Raj Kamboj told PTI.
 When asked about company’s ambitions from the programme over the next two-three years, he said, "Lupin will focus NDDD activities to advance pipeline programs where there are first-to-market and/or best-in-class opportunities. Emphasis will be stressed on designing compounds that are differentiated in their respective class. This in turn will create attractive partnering opportunities." 
Sharing details, Kamboj said the the Mumbai-based company is currently working on developing various products, including two major ones to treat chronic kidney diseases and lung cancer.
 Lupin currently utilises its Pune-based research and development centre for NDDD programme. 
Last month, AbbVie licensed Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein1) inhibitor programme. Through this partnership, AbbVie gains exclusive global rights to develop and commercialise MALT1 inhibitors. Under the terms of the agreement with AbbVie, Lupin is entitled for an upfront payment of USD 30 million. Upon successful completion of regulatory, development and commercial milestones, the company is eligible to receive total milestone payments of up to USD 947 million.
 Additionally, Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the programme in India, the company added. 
"The deal with AbbVie is a tribute to the outstanding scientific and technical progress that NDDD has been able to achieve," Kamboj said. PTI MSS ANS

Source:https://www.businesstoday.in/pti-feed/lupin-developing-new-products-to-treat-cancer-other-diseases/story/309559.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more